Article
Oncohistone interactome profiling uncovers contrasting oncogenic mechanisms and identifies potential therapeutic targets in high grade glioma.
Acta neuropathologica - 1 Nov 2022
Siddaway Robert, Canty Laura, Pajovic Sanja, Milos Scott, Coyaud Etienne, Sbergio Stefanie-Grace, Vadivel Anguraj Arun Kumaran, Lubanszky Evan, Yun Hwa Young, Portante Alessia, Carette Sheyenne, Zhang Cunjie, Moran Michael F, Raught Brian, Campos Eric I, Hawkins Cynthia
Abstract excerpt
Histone H3 mutations at amino acids 27 (H3K27M) and 34 (H3G34R) are recurrent drivers of pediatric-type high-grade glioma (pHGG). H3K27M mutations lead to global disruption of H3K27me3 through dominant negative PRC2 inhibition, while H3G34R mutations lead to local losses of H3K36me3 through inhibition of SETD2. However, their broader oncogenic mechanisms remain unclear. We characterized the H3.1K27M, H3.3K27M and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.